CMS's proposed 2027 clinical lab fee schedule would cut rates by an average of 16% across 1,500 tests, with genomic and ...
Data from a switch study show that transitioning patients from weekly to less-frequent dosing of subcutaneous VK2735 can ...
In parallel with its efforts to obtain a biologics designation for retatrutide, Eli Lilly has been pushing for greater FDA ...
Fondazione Telethon ETS' Waskyra was the lone approval under the Collaboration on Gene Therapies Global Pilot, launched in ...
Beauty brands' race to claim emerging science is producing a lot of data and not enough evidence, says Nulastin founder Leah ...
The companies announced positive topline results from the Phase III FUSION trial, with statistically significant improvement ...
The KIT antagonist barzolvolimab demonstrated efficacy in chronic spontaneous urticaria, including in individuals refractory ...
A second FDA complete response letter cited a new inspection of another site involved in producing the radicular leg pain ...
The CD40 ligand-targeted dazodalibep has been closely watched and viewed as high-risk based on past efforts in Sjögren's ...
The US Food and Drug Administration’s traditional, rather than accelerated, approval of Ultragenyx Pharmaceuticals ’ gene ...
More promising Phase II results for the Swiss major's dual GLP-1/GIP receptor agonist in people with type 2 diabetes and ...
Withings is launching StethO Sense, a third-party service that analyzes cardiac and respiratory sounds in children and adults ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results